Cambrex to buy SK Capital-owned Halo Pharma for $425 mln
Cambrex Corp (NYSE: CBM) has agreed to acquire Halo Pharma, a dosage form contract development and manufacturing organization (CDMO). Cambrex agreed to buy Whippany, New Jersey- and Montréal-based Halo for about US$425 million. The deal is expected to close in Q3 2018. The seller is U.S. private equity firm SK Capital Partners, which made a control investment in Halo in 2015. Cambrex, an East Rutherford, New Jersey-based provider of products and services for the development and commercialization of small molecule therapeutics, said the deal will allow it to enter the CDMO market.
25 July 2018•5 mins read
